A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
PloS one, Volume 13, Issue 12, 2018, Pages 1-12.
Checkpoint inhibitor immunotherapies have had major success in treating patients with late-stage cancers, yet the minority of patients benefit. Mutation load and PD-L1 staining are leading biomarkers associated with response, but each is an imperfect predictor. A key challenge to predicting response is modeling the interaction between the...More
PPT (Upload PPT)